EphA2 Antibody (3D7): sc-135658
- EphA2 Antibody (3D7) is a mouse monoclonal IgG2b, cited in 1 publications, provided at 50 µg/500 µl
- raised against amino acids 559-976 corresponding to recombinant EphA2 of human origin
- recommended for detection of EphA2 of mouse, rat and human origin by WB, IP and ELISA
- See EphA2 (C-3): sc-398832 for EphA2 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for EphA2 Antibody (3D7). This work is in progress.
EphA2 Antibody (3D7) is a mouse monoclonal IgG2b light chain antibody that detects EphA2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). EphA2 is a member of the Eph receptor family, which represents the largest group of receptor protein tyrosine kinases identified to date, playing a crucial role in various biological processes, including cell signaling, development, and the functioning of the central nervous system. EphA2 protein is primarily located on the cell surface, where EphA2 interacts with ephrin-A2 and ephrin-A4 ligands to mediate bidirectional signaling that influences cell adhesion, migration, and tissue organization. This spatial localization is vital as EphA2 participates in the regulation of cellular interactions and communication, which are essential for processes such as angiogenesis and neural development. Anti-EphA2 antibody (3D7) is an invaluable tool for researchers studying these pathways and their implications in health and disease, including cancer progression and neurodegenerative disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EphA2 Antibody (3D7) References:
- EphA2 is a functional entry receptor for HCMV infection of glioblastoma cells. | Dong, XD., et al. 2023. PLoS Pathog. 19: e1011304. PMID: 37146061
- Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer. | Tröster, A., et al. 2023. ChemMedChem. 18: e202300420. PMID: 37736700
- Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers. | Li, X., et al. 2023. Cell Death Dis. 14: 662. PMID: 37816703
- EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections. | Vincenzi, M., et al. 2024. Curr Med Chem. 31: 5670-5701. PMID: 37828671
- An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. | Chang, FL., et al. 2023. Biochem Biophys Res Commun. 688: 149214. PMID: 37951154
- EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer. | Li, Y., et al. 2023. Aging (Albany NY). 15: 12952-12965. PMID: 37980165
- Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation. | Zeng, J., et al. 2023. Biomed Pharmacother. 169: 115885. PMID: 37984301
- Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer. | Veiga, RN., et al. 2024. J Mol Med (Berl). 102: 479-493. PMID: 38393661
- Receptor Tyrosine Kinase EPHA2 Drives Epidermal Differentiation through Regulation of EGFR Signaling. | Perez White, BE., et al. 2024. J Invest Dermatol. 144: 1798-1807.e1. PMID: 38520417
- EPHA2 Regulates SOX2 during Esophageal Development. | Li, T., et al. 2024. bioRxiv.. PMID: 39416037
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EphA2 Antibody (3D7) | sc-135658 | 50 µg/500 µl | $322.00 |